Piper Jaffray Companies Reaffirms Buy Rating for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ:HOLX)‘s stock had its “buy” rating reissued by equities researchers at Piper Jaffray Companies in a research report issued to clients and investors on Thursday, November 9th. They currently have a $48.00 price target on the medical equipment provider’s stock. Piper Jaffray Companies’ price target points to a potential upside of 18.67% from the company’s previous close.

HOLX has been the subject of several other reports. Royal Bank Of Canada reduced their target price on Hologic from $50.00 to $45.00 and set a “sector perform” rating for the company in a research note on Thursday, August 3rd. BidaskClub downgraded Hologic from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Zacks Investment Research upgraded Hologic from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. Barclays dropped their price target on shares of Hologic from $53.00 to $51.00 and set an “overweight” rating on the stock in a research report on Thursday, August 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $50.00 price target on shares of Hologic in a research report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the stock. Hologic currently has a consensus rating of “Buy” and a consensus target price of $47.54.

Shares of Hologic (HOLX) opened at $40.45 on Thursday. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.79 and a quick ratio of 0.61. The company has a market capitalization of $11,150.00, a PE ratio of 20.23, a PEG ratio of 1.98 and a beta of 0.93. Hologic has a 12 month low of $35.76 and a 12 month high of $46.80.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The company had revenue of $802.90 million during the quarter, compared to the consensus estimate of $792.54 million. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The firm’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period last year, the business posted $0.52 EPS. analysts anticipate that Hologic will post 2.12 earnings per share for the current year.

In other news, Director Lawrence M. Levy sold 7,138 shares of the business’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $37.38, for a total transaction of $266,818.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Karleen Marie Oberton sold 1,256 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $39.29, for a total transaction of $49,348.24. Following the transaction, the vice president now owns 9,406 shares of the company’s stock, valued at $369,561.74. The disclosure for this sale can be found here. Insiders sold a total of 35,972 shares of company stock valued at $1,385,977 over the last quarter. 0.79% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC purchased a new position in shares of Hologic during the 3rd quarter valued at $618,000. GSA Capital Partners LLP grew its position in shares of Hologic by 379.5% during the 3rd quarter. GSA Capital Partners LLP now owns 63,760 shares of the medical equipment provider’s stock valued at $2,339,000 after purchasing an additional 50,463 shares in the last quarter. Americafirst Capital Management LLC purchased a new position in shares of Hologic during the 3rd quarter valued at $554,000. IFM Investors Pty Ltd purchased a new position in shares of Hologic during the 3rd quarter valued at $335,000. Finally, Ladenburg Thalmann Financial Services Inc. grew its position in shares of Hologic by 66.4% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,487 shares of the medical equipment provider’s stock valued at $458,000 after purchasing an additional 4,984 shares in the last quarter. Hedge funds and other institutional investors own 93.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Piper Jaffray Companies Reaffirms Buy Rating for Hologic (NASDAQ:HOLX)” was first published by BBNS and is the sole property of of BBNS. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://baseballnewssource.com/markets/hologics-holx-buy-rating-reaffirmed-at-piper-jaffray-companies/1771777.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.